Supernus Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Supernus Pharmaceuticals has a total shareholder equity of $957.5M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $1.3B and $358.4M respectively. Supernus Pharmaceuticals's EBIT is $40.6M making its interest coverage ratio -3.7. It has cash and short-term investments of $347.2M.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | -3.7x |
| Cash | US$347.19m |
| Equity | US$957.45m |
| Total liabilities | US$358.38m |
| Total assets | US$1.32b |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0LB2's short term assets ($591.0M) exceed its short term liabilities ($308.7M).
Long Term Liabilities: 0LB2's short term assets ($591.0M) exceed its long term liabilities ($49.7M).
Debt to Equity History and Analysis
Debt Level: 0LB2 is debt free.
Reducing Debt: 0LB2 has no debt compared to 5 years ago when its debt to equity ratio was 69%.
Debt Coverage: 0LB2 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 0LB2 has no debt, therefore coverage of interest payments is not a concern.